March 9, 2017Open Access

Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors

Key Points

Key points are not available for this paper at this time.

Abstract

Because GRPR is overexpressed in a high percentage of ER-positive tumors, GRPR targeting offers wide perspectives for imaging and treatment in patients with ER-positive breast cancer, using recently developed radiolabeled GRPR ligands.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Morgat et al. (Thu,) studied this question.

synapsesocial.com/papers/6a033e4a200d7a04bd755d99 https://doi.org/https://doi.org/10.2967/jnumed.116.188011

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer2010 · 64 citations
2Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers2015 · 33 citations
3Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues2014 · 11 citations
4Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.1995 · 125 citations
5Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors2017 · 3,200 citations

AI से पूछें

Bookmark

View Full Paper